Gastric Cancer

NMPA grants BTD to Innovent’s olverembatinib to treat SDH-deficient GIST

The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted breakthrough therapy designation (BTD) to Innovent Biologics’ olverembatinib for the treatment of succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumour (GIST).

Daiichi Sankyo and AstraZeneca’s ENHERTU gets approval in EU

Daiichi Sankyo and AstraZeneca’s ENHERTU (trastuzumab deruxtecan) has secured approval in the European Union (EU) as a monotherapy to treat adult patients with advanced HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received an earlier trastuzumab-based regimen.

Prestige BioPharma and Dr. Reddy’s partner to sell trastuzumab biosimilar

Prestige BioPharma and Dr. Reddy’s Laboratories have signed a binding agreement to commercialise the former’s trastuzumab (HD201) biosimilar in select Latin America and Southeast Asian countries.

Ambrx gets orphan drug designation for gastric cancer treatment ARX788

The US Food and Drug Administration (FDA) grants orphan drug designation to Ambrx for ARX788, a homogeneous and highly stable antibody drug conjugate, for the treatment of HER2-positive gastric cancer.

Amgen signs agreement to acquire Five Prime Therapeutics for $1.9bn

Clinical-stage biotechnology company Amgen has signed an agreement to acquire Five Prime Therapeutics for $38.00 per share in cash, representing an equity value of around $1.9bn. 

Etana to launch Innovent Biologics’ cancer drug BYVASDA in Indonesia

Chinese pharmaceutical company Innovent Biologics has signed an out-license agreement with Etana Biotechnologies to develop and commercialise cancer drug BYVASDA (Bevacizumab Biosimilar) in Indonesia.